PRESS RELEASE published on 10/10/2025 at 22:11, 1 year ago Inside Information / Other news releases FDA approves UZEDY as extended-release injectable suspension for bipolar I disorder treatment in adults. Teva and Medincell collaborate on this significant advancement in neuroscience FDA Medincell Teva UZEDY Bipolar I Disorder
BRIEF published on 09/17/2025 at 14:05, 1 year ago Medincell and Teva Present Phase 3 Olanzapine LAI Data Phase 3 Trial Schizophrenia Treatment Medincell Teva Olanzapine LAI
PRESS RELEASE published on 09/17/2025 at 14:00, 1 year ago Inside Information / Other news releases Medincell and Teva to discuss Phase 3 Olanzapine LAI data from SOLARIS Trial at 2025 Psych Congress. Webcast details available on Teva's IR website Phase 3 Medincell Teva SOLARIS Trial Olanzapine LAI
BRIEF published on 09/12/2025 at 07:35, 1 year 1 month ago Medincell Appoints Three New Board Members Innovation Biopharmaceutical Leadership Board Appointments Medincell
PRESS RELEASE published on 09/12/2025 at 07:30, 1 year 1 month ago Inside Information / Other news releases Medincell appoints Dr. Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon to its Board of Directors, adding valuable expertise in biotech and pharmaceutical sectors Board Of Directors Medincell Dr. Sharon Mates Dr. Charles Kunsch Dr. Pascal Touchon
BRIEF published on 09/10/2025 at 21:46, 1 year 1 month ago UZEDY® Obtains Approval in South Korea Following Success in the United States Schizophrenia UZEDY Teva Handok Medical Supply Korean Market
PRESS RELEASE published on 09/10/2025 at 21:41, 1 year 1 month ago Inside Information / Other news releases Teva Handok announces regulatory approval for UZEDY® in South Korea by Ministry of Food and Drug Safety, following successful US launch. Medincell's long-acting injectable for schizophrenia shows strong commercial performance Regulatory Approval Schizophrenia Medincell Commercial Performance Teva Handok
BRIEF published on 08/04/2025 at 14:05, 1 year 2 months ago Medincell Announces its 2025 General Meeting Governance General Meeting Resolutions Remuneration Medincell
BRIEF published on 07/30/2025 at 14:34, 1 year 2 months ago Medincell's Rising Revenue and Upcoming Submissions Schizophrenia Treatment Teva Partnership Medincell Revenue UZEDY Sales Olanzapine Submission
PRESS RELEASE published on 07/30/2025 at 14:29, 1 year 2 months ago INSIDE INFORMATION / OTHER NEWS RELEASES Medincell's partner Teva Pharmaceuticals raises 2025 revenue outlook for UZEDY® to $190–$200M and confirms Olanzapine LAI on track for submission in 2025 Revenue Outlook Medincell Teva Pharmaceuticals Olanzapine LAI Submission
Published on 10/16/2026 at 08:00, 20 minutes ago Caledonia Mining Corporation Plc: Notification of Relevant Change to Significant Shareholder
Published on 10/16/2026 at 05:55, 2 hours 25 minutes ago Collective Metals Announces Private Placement of Hard Dollar and Flow-Through Units
Published on 10/16/2026 at 02:10, 6 hours 10 minutes ago Nova Scotia Silver Explorer TruSilver Metals Corp. Anticipates TSXV Trading Under "TAG" on October 27
Published on 10/16/2026 at 01:45, 6 hours 35 minutes ago Faraday Copper Closes the Acquisition of the San Manuel Project in Arizona and Mobilizes Drill Rigs
Published on 10/16/2026 at 01:30, 6 hours 50 minutes ago LNG Energy Group Announces Closing of Second Tranche of Private Placement
Published on 10/16/2026 at 07:30, 50 minutes ago Steyr Motors and drone specialist Avilus are cooperating on the power supply for the Grille unmanned aircraft system
Published on 10/16/2026 at 07:00, 1 hour 20 minutes ago PolyPeptide Group: Definitive interim result of the public tender offer of Samsung Biologics Co., Ltd.
Published on 10/15/2026 at 22:30, 9 hours 50 minutes ago Porsche Mission S: the essence of the sports car reinterpreted
Published on 10/15/2026 at 18:50, 13 hours 30 minutes ago September & first 9 months of 2026 traffic figures - Revision of Traffic assumptions for 2026
Published on 10/15/2026 at 17:45, 14 hours 35 minutes ago DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
